Passage BIO, Inc. (PASG): Depreciation & Amortization
$728.0K
Year ended 2025-12-31
$512.0K
Trailing 12 months to 2026-06-30
-41.7%
3-year compound annual growth
-1.9%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $728.0K | -76.4% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $3.08M | -17.2% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $3.72M | +1.1% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $3.68M | +138.4% | 2024-03-04, From 2022-01-01 |
| 2021-12-31 | $1.54M | +92.9% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $800.0K | +497.0% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $134.0K | n/a | 2021-03-03, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $728.0K | -76.4% |
| Elutia Inc. (ELUT) | 2025-12-31 | $2.79M | -19.3% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $364.0K | -9.9% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $3.96M | -22.4% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2024-12-31 | $1.32M | +36.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $58.6K | -27.9% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $36.0K | -66.4% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $664.0K | -6.2% |
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | $142.0K | -23.7% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗